Where Are They Now · Profile 16
Martin Landray
Professor Sir Martin J. Landray (University of Oxford).
Claims are labeled Documented, Allegation or Open question. An allegation or open question is not a finding of wrongdoing. "Excessive"/"toxic" dose characterizations come from the film's interviewees (Hatfill, Meehan) and critics.
Who he was in the COVID era
- Co-Chief Investigator of the UK RECOVERY trial (with Peter Horby). Professor at Oxford's Nuffield Department of Population Health. Documented Source: Oxford expert page
- RECOVERY's HCQ dose: 2,400 mg in the first 24 hours (800 mg loading, then 800 mg at 6 h, 400 mg at 12 h and 24 h), then 400 mg every 12 hours through day 10. That is far above the usual lupus/RA dosing. Documented (NEJM protocol/appendix,) Source: NEJM, RECOVERY HCQ (2020)
- Notorious interview (France Soir, Jun 2020). He justified the dose: "The doses were chosen on the basis of pharmacokinetic modeling. These are in line with the sort of doses that you use for amoebic dysentery." Asked about the lethal level: "something like ten times that." Documented (interview; film 00:26:43)
- Critics' charge: Meehan (film 00:26:27) and others said he confused hydroxychloroquine with hydroxyquinoline (an amoebicide), and that the doses were excessive (Hatfill, 00:27:02). Allegation
- RECOVERY's response: co-investigator Horby said the interview misreported "amoebic liver abscess," for which chloroquine was historically used at comparable doses. Documented (secondary rebuttal; find the primary) Source: Palmer Foundation summary (critic)
- India's ICMR wrote to WHO that the trial doses were about 4x higher than India's. Documented (reporting,) Source: New Indian Express, May 29, 2020
- His X posts Documented:
- Mar 24, 2020 (post): "…approval to commence hydroxychloroquine arm applied for."
- May 29, 2020 (post), quoting Nature: "Within a day of the Lancet paper's publication, the UK's RECOVERY trial… consulted its safety board… found no sign of harm to study pts from hydroxychloroquine"
- Jun 5, 2020 (post): "Today's preliminary results from the RECOVERY trial are quite clear – hydroxychloroquine does not reduce the risk of death among hospitalised patients with this new disease."
- Oct 7, 2020 (post): "Dexamethasone improves survival. Remdesivir shortens time to recovery. Hydroxychloroquine & lopinavir are ineffective. we know because the clinical trials have been done"
- Credit: RECOVERY also established that dexamethasone reduces COVID deaths. Documented (fairness note for the page) Source: RECOVERY HCQ statement, Jun 5, 2020
In the film: clips and timecodes
- 00:26:27 — Meehan: Landray "misinterpreting hydroxyquinolone for hydroxychloroquine" (Meehan (critic))
- 00:26:43–00:26:59 — "Let me explain. The doses were chosen on the basis of pharmacokinetic modeling… amoebic dysentery… something like ten times that." (Landray (France Soir audio))
- 00:27:02 — Hatfill: doses excessive (Hatfill (critic))
- Full timecodes are in the annotated transcript.
How COVID-era money shows up in the record
- The film (Bigtree, 00:25:39) says Wellcome and the Gates Foundation funded RECOVERY in part. Allegation (the film's claim)
- No personal payments were found in the records reviewed.
Consequences
- No discipline. He was knighted in the Queen's Birthday Honours, Jun 2021, "for services to public health and science." Documented Source: RECOVERY news
Where is he now
- Oxford professor, CEO of Protas (a non-profit for large clinical trials), and lead of the Good Clinical Trials Collaborative, per his X bio and Oxford pages. Documented Source: Green Templeton College
Top sources
Last reviewed November 2026 (research pass Nov. 2–3, 2026). This profile is updated as new records surface. Corrections: Press@EpidemicOfFraud.com